申请人:Boehringer Ingelheim KG
公开号:US04316898A1
公开(公告)日:1982-02-23
Cephalosporins of the formula ##STR1## wherein A is phenyl, 4-hydroxyphenyl, cyclohexyl, cyclohexene-1-yl, cyclohexa-1,4-diene-1-yl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl or 3,4-disubstituted phenyl, where the substituents, which may be identical to or different from each other, are each chlorine, hydroxyl or methoxy; Y is hydrogen or methoxy; D is hydrogen, hydroxyl, acetoxy, aminocarbonyloxy, pyridinium, aminocarbonyl-pyridinium or the group S-Het, where Het is 1-methyl-tetrazol-5-yl, tetrazol-5-yl, 3-methyl-1,2,4-thiadiazol-5-yl, 1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-5-yl, 2-methyl-1,3,4-thiadiazol-5-yl, 2-methylamino-1,3,4-thiadiazol-5-yl, 2-dimethylamino-1,3,4-thiadiazol-5-yl, 2-formylamino-1,3,4-thiadiazol-5-yl, 2-acetylamino-1,3,4-thiadiazol-5-yl, 2-methyl-1,3,4-oxadiazol-5-yl, 1,2,3-triazol-4-yl or 1,2,4-triazol-3-yl; R is hydrogen, methyl, cyclopropyl, hydroxyl, methoxy, ethoxy, mercapto, morpholino, thiomorpholino, thiomorpholino-S-oxide, thiomorpholino-S,S-dioxide, ##STR2## E is hydrogen or a protective group which is easily removable in vitro or in vivo; and nontoxic, pharmacologically acceptable salts thereof.
式##STR1##中的头孢菌素,其中A是苯基、4-羟基苯基、环己基、环己烯-1-基、环己烯-1,4-二烯-1-基、2-噻吩基、3-噻吩基、2-呋喃基、3-呋喃基或3,4-二取代苯基,其中取代基可以相同也可以不同,每个取代基分别是氯、羟基或甲氧基;Y是氢或甲氧基;D是氢、羟基、乙酰氧基、氨基甲酰氧基、吡啶基、氨基甲酰基-吡啶基或基团S-Het,其中Het是1-甲基-噻唑-5-基、噻唑-5-基、3-甲基-1,2,4-噻二唑-5-基、1,2,4-噻二唑-5-基、1,3,4-噻二唑-5-基、2-甲基-1,3,4-噻二唑-5-基、2-甲氨基-1,3,4-噻二唑-5-基、2-二甲氨基-1,3,4-噻二唑-5-基、2-甲酰氨基-1,3,4-噻二唑-5-基、2-乙酰氨基-1,3,4-噻二唑-5-基、2-甲基-1,3,4-噻二唑-5-基、1,2,3-三唑-4-基或1,2,4-三唑-3-基;R是氢、甲基、环丙基、羟基、甲氧基、乙氧基、巯基、吗啉基、硫代吗啉基、硫代吗啉基-S-氧化物、硫代吗啉基-S,S-二氧化物,##STR2## E是氢或容易在体外或体内去除的保护基;以及其无毒、药理学上可接受的盐。